Quoin Pharmaceuticals financials
$4.88−7.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$16.3M | -$9.5M | -$9.4M | -$9.3M | -$6.1M |
| Net income | -$15.8M | -$9.0M | -$8.7M | -$9.4M | -$21.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-14.80 | $-68.02 | $-337.40 | $-1638.35 | $-28543.20 |
| EBITDA | -$16.2M | -$9.4M | -$9.3M | -$9.2M | -$6.0M |
| Operating cash flow | -$13.5M | -$7.9M | -$7.9M | -$8.5M | -$5.7M |
| Free cash flow | -$13.5M | -$7.9M | -$7.9M | -$8.5M | — |
| Diluted shares | 1.1M | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $3.8M | $3.6M | $2.4M | $2.9M | $7.5M |
| Short-term investments | $14.9M | $10.4M | $8.3M | $10.0M | $715.5K |
| Total debt | $1.1M | $1.1M | $1.1M | $1.1M | $743.8K |
| Total assets | $20.4M | $15.7M | $12.2M | $14.5M | $9.4M |
| Total liabilities | $7.3M | $6.5M | $6.5M | $7.1M | $8.7M |
| Shareholders' equity | $13.1M | $9.2M | $5.7M | $7.4M | $657.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology